One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Record caution: Renal endpoint needs clarification at exactly 15 mL/min; section 8.7 and the PK population use different inequality wording.
Section 8.7 uses below 15 for avoidance and above 15 for usual dosing; the PK analysis includes at least 15. Exactly 15 is therefore not consistently assigned across the selected sections.
What to reconcile: Seek exact-label clarification at this endpoint. Do not round, silently change an inequality, or apply indexed eGFR when the source uses a BSA-adjusted measure.
Open this note and its source referencesThe official recheck retains the same greater-than versus greater-than-or-equal boundary distinction seen in the mirror.
What to reconcile: Do not assign exact 15 from the PK paragraph or change absolute mL/min to indexed units. Obtain product-specific clarification.
Open this note and its source referencesAvoid JOURNAVX at eGFR below 15 mL/min; that population was not studied. Section 8.7 states usual dosing above 15, whereas the PK analysis includes eGFR at least 15 using CKD-EPI adjusted for body surface area. Exactly 15 therefore needs boundary clarification; no automatic choice is made. For eligible adults with acute pain, the usual regimen is 100 mg initially on an empty stomach, then 50 mg every 12 hours starting 12 hours later. Use beyond 14 days was not studied. Strong CYP3A inhibitors are contraindicated; moderate inhibitors and hepatic impairment require separate adjustments. This is not a dialysis-specific regimen.
RDM36-official-suzetrigine-journavx-90f3d04d76-C1 · Source locator: Sections 2.1, 2.3, 8.7 and 12.3; highlights revision.
DailyMed page updated April 13, 2026; source revision and retrieval dates remain separate. RX fetch failure remains unresolved.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=suzetrigine-journavx&s1=RDM36-official-suzetrigine-journavx-90f3d04d76&h1=d4d4703af0e420ab97bcdbc9c8783dacf23d2553222728ec832171916bb2f959